Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Sara Tolaney, MD, MPH, and Komal Jhaveri, MD, FACP, on Wednesday, October 7, 2020 at 8 PM EDT.
Exclusive for NYC and Boston Breast Cancer Specialists
An OncLive® Panel Presentation Series
Therapeutic Considerations in Metastatic HER2+ Breast Cancer
What are the latest options? How are advances today impacting the decisions a physician must make of tomorrow?
Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Sara Tolaney, MD, MPH, and Komal Jhaveri, MD, FACP.
Topics of discussion at this virtual event include:
Review and evaluate data on recent therapeutic advances in metastatic HER2+ breast cancer
Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with metastatic HER2+ breast cancer
Identify factors that influence treatment selection and planning for patients with metastatic HER2+ breast cancer
Speakers:
Komal Jhaveri, MD, FACP Assistant Attending Physician, Breast Medicine and Early Drug Development Service Section Head, Endocrine Therapy Memorial Sloan Kettering Cancer Center Assistant Professor, Department of Medicine, Weill Cornell Medical College
Sara Tolaney, MD, MPH Assistant Professor of Medicine Harvard Medical School Associate Director, Susan F. Smith Center for Women's Cancers Director of Clinical Trials, Breast Oncology Director of Breast Immunotherapy, Breast Oncology Dana-Farber Cancer Institute Boston, MA